바로가기  >

Abstract
To evaluate the efficacy of proton beam therapy (PBT) as an initial treatment in treatment-naïve hepatocellular carcinoma (HCC) patients and to assess the prognostic significance of albumin-bilirubin (ALBI) grade, 46 treatment-naïve HCC patients treated with PBT were analyzed. The ALBI grade distribution was grade 1 in 11 (23.9%) patients, grade 2 in 34 (73.9%) patients, and grade 3 in 1 (2.2%) patient. The median duration of follow-up was 56.5 months (95% confidence interval [CI], 48.2-64.7). Among the 46 patients, disease progression was observed in 23 (50%) patients: local progression in 3 (6.5%) patients; intrahepatic progression in 22 (47.8%); and extrahepatic progression in 5 (10.9%). The 5-year freedom from local progression (FFLP), progression-free survival (PFS), and overall survival (OS) rates were 92.7% (95% CI, 84.7-100.7), 43.3% (95% CI, 28.2-58.4), and 69.2% (95% CI, 54.9-83.5), respectively. In multivariate analysis, there were no independent factors for FFLP (p > 0.05 each), but tumor stage and ALBI grade were independent factors for PFS and OS (p < 0.05 each). PBT could result in comparable OS in treatment-naïve HCC patients to other recommended first-line treatments, and ALBI grade, in addition to tumor stage, could be useful for predicting OS.

Affiliations

Tae Hyun Kim 1 2, Bo Hyun Kim 1, Joong-Won Park 1, Yu Ri Cho 1, Young-Hwan Koh 1, Jung Won Chun 1, Eun Sang Oh 2, Do Yeul Lee 2, Sung Uk Lee 2, Yang-Gun Suh 2, Sang Myung Woo 1, Sung Ho Moon 2, Sang Soo Kim 2, Woo Jin Lee 1
1Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang 10408, Korea.
2Center for Proton Therapy, National Cancer Center, Goyang 10408, Korea.